Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR439459 Monotherapy and with Cemiplimab in Advanced Solid Tumors
NCT03192345Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jun 2017
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 1, randomised, open-label trial of SAR439459 in solid tumor (advanced stage), melanoma, colorectal adenocarcinoma and 3 more (4 arms), sponsored by Sanofi. Primary endpoints: Incidence of Dose Limiting Toxicities at 6 weeks and Objective Response Rate at 1 year. Started Jun 2017; status: completed.
02
Drugs
SAR439459
03
Conditions
solid tumor (advanced stage)melanomacolorectal adenocarcinomaurothelial carcinoma (UC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03192345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192345.